Another New Patent Issues for Regenexx

By /

regenexx patent

We have been awarded several US patents of late on the Regenexx procedure. These things take forever to process, with most of these being filed many years ago. They continue to define the difference between Regenexx and everything else.

Anti-inflammatory steroids are a two edged sword, on the one hand when used in the super-physiologic doses commonly used by almost all physicians (approximately one million times the dose that they body normally sees), they can cause tissue damage. This is the milligram dose range. However, when used in doses of a million times less, the nanogram range, different things happen. In fact in that dose range they are powerful signals for stem cells to turn into cartilage cells. In addition, this is a physiologic dose that the body sees and uses itself everyday.

The new Regenexx patent continues to protect our proprietary procedure by allowing a Regenexx physician to use platelet growth factors in combination with stem cells and a nanogram dose of steroid to help cartilage repair. This fits hand in glove with the patent we were granted earlier this year that uses an inflammation causing agent to ramp up stem cell activity. Many more patients on more proprietary parts of the procedure are pending.

The upshot? I’ve been saying for years that Regenexx is different, but we’ve been waiting for these core patents to issue to discuss in more detail why it’s different. In essence, it’s always been the second phase beyond simple stem cell therapy, where stem cells and perhaps some PRP are injected in a joint. Instead, we’ve long since recognized that the simple “stem cell procedure” was often not enough to get the job done (something that everyone else just now throwing their hat in the stem cell ring will eventually realize). We’ve also been hard at work creating new advances, including our phase 3 procedure, which will measure and then customize the micro environment inside a joint to an individual patient’s needs. That process I’m sure will again generate new intellectual property, keeping Regenexx unique and far ahead of the pack for many years to come.

Join us for a free Regenexx webinar.
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

Get Blog Updates by Email

By submitting the form, you are agreeing that you read and consent to our Privacy Policy. We may also contact you via email, phone, and other electronic means to communicate information about our products and services. We do not sell, or share your information to third party vendors.

Copyright © Regenexx 2021. All rights reserved.



9035 Wadsworth Pkwy #1000
Westminster, CO 80021


*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.